Provided by Tiger Fintech (Singapore) Pte. Ltd.

Praxis Precision Medicines, Inc.

35.34
+1.554.59%
Post-market: 36.771.43+4.05%17:32 EDT
Volume:558.77K
Turnover:19.73M
Market Cap:712.57M
PE:-3.46
High:36.70
Open:33.48
Low:32.78
Close:33.79
Loading ...

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
01 Mar

Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges

TIPRANKS
·
01 Mar

Praxis Precision downgraded to Underperform from Neutral at Wedbush

TIPRANKS
·
01 Mar

Top Midday Decliners

MT Newswires Live
·
01 Mar

Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment

TIPRANKS
·
01 Mar

H.C. Wainwright sees opportunity for quick rebound from Praxis after setback

TIPRANKS
·
01 Mar

Praxis Still Seen a Buy Despite Essential Tremor Bump -- Market Talk

Dow Jones
·
01 Mar

Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position

TIPRANKS
·
01 Mar

Praxis Precision price target lowered to $85 from $175 at Truist

TIPRANKS
·
01 Mar

Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge

MT Newswires Live
·
01 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

Praxis Precision Medicines Shares Slide on Study Setback

Dow Jones
·
28 Feb

Praxis Precision Medicines Shares Slump 39% After Independent Committee Recommends Tremor Drug Trial Be Stopped for Futility

THOMSON REUTERS
·
28 Feb

BUZZ-Praxis slumps as anti-tremor drug study unlikely to meet the main goal

Reuters
·
28 Feb

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program

MT Newswires Live
·
28 Feb

Praxis Precision Medicines Shares Plunge 38.5% Premarket After Independent Committee Recommends Tremor Drug Trial Be Stopped for Futility

THOMSON REUTERS
·
28 Feb

Praxis Precision: Panel Recommends Stopping Essential Tremor Study for Futility

Dow Jones
·
28 Feb

Independent committee says Praxis' tremor drug trial unlikely to meet main goal

Reuters
·
28 Feb

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

THOMSON REUTERS
·
28 Feb